USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
Address: 535 West Second Street
Suite 10
Lexington, KY 40508
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,290,649.00 5
SBIR Phase II $2,966,575.00 2

Award List:

L1 mutagenesis for mammalian models of human diseases

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eric M. Ostertag
Award Amount: $99,724.00
Abstract:
DESCRIPTION (provided by applicant): Transposagen is developing an innovative mammalian random mutagenesis system that uses an L1 retrotransposon for direct germ-line mutagenesis. Transposagen's goal is to produce "mutator rats". In these rats, mutagensis will occur in sperm and some offspring will… More

L1 retrotransposon-based mutagenesis for rat models of human diseases

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Eric M. Ostertag
Award Amount: $1,318,986.00
Abstract:
DESCRIPTION (provided by applicant): In many aspects the rat is a better animal model than the mouse for functional genomic studies. The physiology and drug metabolism of rats and humans are more similar than that of mice and humans. The rat is larger than the mouse, making many studies easier to… More

Tissue-Specific Mutagenesis in Rat as an In Vivo Tool for Colon Cancer Gene Disco

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Blair B. Madison
Award Amount: $312,628.00
Abstract:
DESCRIPTION (provided by applicant): The outcome of this SBIR application will be a rat model of colorectal cancer (CRC), which can be used to discover new targets for colon cancer therapy. CRC rats will be produced using Transposagen's novel technology fo r introducing somatic mutations in rats. A… More

Creation of hyperactive transposons for mutagenesis in rodents

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eric M. Ostertag
Award Amount: $295,614.00
Abstract:
DESCRIPTION (provided by applicant): This project aims to rapidly produce rat mutants through a transposon-based method of mutagenesis. The rat is a favored model for many types of human disease for which mice are not suitable. The rat is the most relevant model for cardiovascular and hypertension… More

Generation of Site-Specific Recombinase-Expressing Transgenic Rats using an Enhan

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eric M. Ostertag
Award Amount: $240,637.00
Abstract:
DESCRIPTION (provided by applicant): The goal is to create site-specific recombinase (SSR)-expressing transgenic rats in an efficient and unbiased manner through a transposon-mediated in vivo gene trap. Rats are very relevant for modeling human biology and disease because rats, unlike mice,… More

Creation of hyperactive transposons for mutagenesis in rodents

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Eric M. Ostertag
Award Amount: $1,647,589.00
Abstract:
DESCRIPTION (provided by applicant): The rat is a favored model for many types of human disease for which mice are not suitable. As opposed to the mouse, rats and humans also share more similarity in their cytochrome P450 genes, making the rat a more usefu l model for toxicology and pharmacology… More

Novel method to create knockout rats using endonucleases and spermatagonialstem

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Eric M. Ostertag – 267-259-1086
Award Amount: $342,046.00
Abstract:
DESCRIPTION (provided by applicant): The laboratory rat is the preferred rodent model in pre-clinical drug studies and encompasses the bulk of accumulated knowledge in drug development. Their larger size facilitates procedures otherwise difficult in mice,including studies using instrumentation,… More